TH

Tanner Hamilton

Accounting Manager at Elevation Oncology

Tanner Hamilton has a diverse and extensive work experience as an accountant. Tanner started their career at BDO USA, LLP in 2012 as an Assurance Associate, where they conducted audits and review engagements for various clients. Tanner then transitioned to the role of Risk Advisory Services Associate, assisting in risk management and internal control systems. In 2015, Tanner joined Alaska USA as a Subsidiary Accountant, participating in month-end close and preparing financial reports. Tanner later became a Cost Accountant, developing and administering credit union profit/cost allocations.

In 2017, Tanner joined EMERGO, a UL company, as a Senior Accountant. Tanner performed general accounting work across multiple multinational entities, developed policies and procedures, and provided guidance to junior accountants. Tanner then joined Pathway Vet Alliance in 2019 as a Senior Accountant, analyzing profit and loss accounts, working closely with finance to resolve variances, and analyzing COGS.

Tanner's next role was at Aeglea BioTherapeutics in 2020, where they served as a Senior Accountant for R&D and clinical trial projects. Tanner worked closely with project managers, vendors, and finance to ensure accurate accounting and reviewed contracts for project tracking. Most recently, in 2022, Tanner joined Elevation Oncology as a Senior Accountant. Tanner leads the month-end close process, oversees the work of a staff accountant, and performs balance sheet reconciliations and journal entries.

Tanner Hamilton attended Service High School from 2004 to 2008. From 2009 to 2013, they studied at the University of Alaska Anchorage where they earned a Bachelor of Business Administration degree in Accounting.

Location

Buckeye, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Elevation Oncology

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. They make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease.


Employees

11-50

Links